GLMD Annual CFF
$6.18 M
+$6.12 M+8735.71%
31 December 2023
Summary:
As of January 23, 2025, GLMD annual cash flow from financing activities is $6.18 million, with the most recent change of +$6.12 million (+8735.71%) on December 31, 2023. During the last 3 years, it has risen by +$5.42 million (+705.34%). GLMD annual CFF is now -92.29% below its all-time high of $80.18 million, reached on December 31, 2018.GLMD Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLMD Quarterly CFF
$8.34 M
0.00%
30 September 2024
Summary:
As of January 23, 2025, GLMD quarterly cash flow from financing activities is $8.34 millionOver the past year, it has increased by +$2.15 million (+34.81%). GLMD quarterly CFF is now -89.58% below its all-time high of $80.03 million, reached on June 30, 2018.GLMD Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLMD TTM CFF
$8.34 M
0.00%
30 September 2024
Summary:
As of January 23, 2025, GLMD TTM cash flow from financing activities is $8.34 millionOver the past year, it has increased by +$2.15 million (+34.81%). GLMD TTM CFF is now -91.25% below its all-time high of $95.34 million, reached on June 30, 2018.GLMD TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLMD Cash From Financing Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +8735.7% | +34.8% | +34.8% |
3 y3 years | +705.3% | +34.8% | +34.8% |
5 y5 years | -92.3% | +34.8% | +34.8% |
GLMD Cash From Financing High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -64.4% | +8735.7% | at high | -52.0% | >+9999.0% | |
5 y | 5-year | -64.4% | +8735.7% | -52.0% | -53.9% | >+9999.0% | |
alltime | all time | -92.3% | +8735.7% | -89.6% | +6416.7% | -91.3% | +6416.7% |
Galmed Pharmaceuticals Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | $8.34 M(>+9900.0%) | $8.34 M(+34.8%) |
Dec 2023 | $6.18 M(+8735.7%) | $0.00(-100.0%) | $6.18 M(0.0%) |
Sept 2023 | - | $6.18 M(>+9900.0%) | $6.18 M(+8735.7%) |
Dec 2022 | $70.00 K(-99.6%) | $0.00(-100.0%) | $70.00 K(0.0%) |
Sept 2022 | - | $70.00 K(>+9900.0%) | $70.00 K(-99.6%) |
Dec 2021 | $17.37 M(+2161.5%) | $0.00(0.0%) | $17.37 M(0.0%) |
Sept 2021 | - | $0.00(0.0%) | $17.37 M(-3.9%) |
June 2021 | - | $0.00(-100.0%) | $18.07 M(0.0%) |
Mar 2021 | - | $17.37 M(>+9900.0%) | $18.07 M(+2253.5%) |
Dec 2020 | $768.00 K(+437.1%) | $0.00(-100.0%) | $768.00 K(-5.9%) |
Sept 2020 | - | $707.00 K(>+9900.0%) | $816.00 K(+648.6%) |
June 2020 | - | $0.00(-100.0%) | $109.00 K(-16.2%) |
Mar 2020 | - | $61.00 K(+27.1%) | $130.00 K(-9.1%) |
Dec 2019 | $143.00 K(-99.8%) | $48.00 K(>+9900.0%) | $143.00 K(-31.9%) |
Sept 2019 | - | $0.00(-100.0%) | $210.00 K(-7.5%) |
June 2019 | - | $21.00 K(-71.6%) | $227.00 K(-99.7%) |
Mar 2019 | - | $74.00 K(-35.7%) | $80.24 M(+0.1%) |
Dec 2018 | $80.18 M | $115.00 K(+576.5%) | $80.18 M(-13.5%) |
Sept 2018 | - | $17.00 K(-100.0%) | $92.64 M(-2.8%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
June 2018 | - | $80.03 M(>+9900.0%) | $95.34 M(+512.8%) |
Mar 2018 | - | $12.00 K(-99.9%) | $15.56 M(+0.1%) |
Dec 2017 | $15.55 M(+228.4%) | $12.58 M(+362.3%) | $15.55 M(+423.8%) |
Sept 2017 | - | $2.72 M(+1001.6%) | $2.97 M(-42.0%) |
June 2017 | - | $247.00 K(>+9900.0%) | $5.11 M(+8.0%) |
Mar 2017 | - | $0.00(0.0%) | $4.73 M(0.0%) |
Dec 2016 | $4.73 M(-88.7%) | $0.00(-100.0%) | $4.73 M(0.0%) |
Sept 2016 | - | $4.87 M(-3786.4%) | $4.73 M(-3686.4%) |
June 2016 | - | -$132.00 K(<-9900.0%) | -$132.00 K(<-9900.0%) |
June 2015 | - | $0.00(0.0%) | $0.00(-100.0%) |
Dec 2014 | $41.86 M(+2057.5%) | $0.00(0.0%) | $41.86 M(-1.9%) |
Sept 2014 | - | $0.00(0.0%) | $42.65 M(-2.7%) |
June 2014 | - | $0.00(-100.0%) | $43.82 M(0.0%) |
Mar 2014 | - | $41.86 M(+5164.9%) | $43.82 M(+2158.6%) |
Dec 2013 | $1.94 M(-47.3%) | $795.00 K(-31.8%) | $1.94 M(+69.4%) |
Sept 2013 | - | $1.17 M(>+9900.0%) | $1.15 M(-5825.0%) |
June 2013 | - | $0.00(-100.0%) | -$20.00 K(0.0%) |
Mar 2013 | - | -$20.00 K | -$20.00 K |
Dec 2012 | $3.68 M | - | - |
FAQ
- What is Galmed Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Galmed Pharmaceuticals?
- What is Galmed Pharmaceuticals annual CFF year-on-year change?
- What is Galmed Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Galmed Pharmaceuticals?
- What is Galmed Pharmaceuticals quarterly CFF year-on-year change?
- What is Galmed Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Galmed Pharmaceuticals?
- What is Galmed Pharmaceuticals TTM CFF year-on-year change?
What is Galmed Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of GLMD is $6.18 M
What is the all time high annual CFF for Galmed Pharmaceuticals?
Galmed Pharmaceuticals all-time high annual cash flow from financing activities is $80.18 M
What is Galmed Pharmaceuticals annual CFF year-on-year change?
Over the past year, GLMD annual cash flow from financing activities has changed by +$6.12 M (+8735.71%)
What is Galmed Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of GLMD is $8.34 M
What is the all time high quarterly CFF for Galmed Pharmaceuticals?
Galmed Pharmaceuticals all-time high quarterly cash flow from financing activities is $80.03 M
What is Galmed Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, GLMD quarterly cash flow from financing activities has changed by +$2.15 M (+34.81%)
What is Galmed Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of GLMD is $8.34 M
What is the all time high TTM CFF for Galmed Pharmaceuticals?
Galmed Pharmaceuticals all-time high TTM cash flow from financing activities is $95.34 M
What is Galmed Pharmaceuticals TTM CFF year-on-year change?
Over the past year, GLMD TTM cash flow from financing activities has changed by +$2.15 M (+34.81%)